Three cases of anti-TNF induced myositis and literature review

Rev Bras Reumatol Engl Ed. 2017 Nov-Dec;57(6):590-595. doi: 10.1016/j.rbre.2016.05.003. Epub 2016 Jun 1.
[Article in English, Portuguese]

Abstract

Anti-tumor necrosis factor drugs are frequently preferred in the treatment of rheumatologic diseases and other inflammatory diseases. The development of myositis after using anti-tumor necrosis factor drugs is a rare clinical condition. Here we aimed to report cases who developed myositis after using anti-tumor necrosis factor drugs and review the current literature. We report two cases of rheumatoid arthritis and a case of ankylosing spondylitis developed idiopathic inflammatory myopathy following anti-tumor necrosis factor therapy. In conclusion, myositis could develop during anti-tumor necrosis factor therapy, so these patients should be evaluated carefully initially for myositis and should be closely monitored due to the potential for developing myositis in treatment process.

Keywords: Anti-tumor necrosis factor (anti-TNF) drugs; Fármacos antifator de necrose tumoral (anti-TNF); Jo-1; Miosite; Myositis.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adalimumab / administration & dosage
  • Adalimumab / adverse effects*
  • Adult
  • Antirheumatic Agents / adverse effects*
  • Arthritis, Rheumatoid / drug therapy
  • Etanercept / administration & dosage
  • Etanercept / adverse effects*
  • Female
  • Humans
  • Male
  • Myositis / chemically induced*
  • Myositis / diagnosis
  • Spondylitis, Ankylosing / drug therapy
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Young Adult

Substances

  • Antirheumatic Agents
  • Tumor Necrosis Factor-alpha
  • Adalimumab
  • Etanercept